20/20 Biolabs, Inc. Common Stock Cash Flow Quality Index
20/20 Biolabs, Inc. Common Stock cash flow quality index. 20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow Quality Index of 2.65x as of December 2022. Operating cash flow of $5.80 Million exceeds net income of $2.19 Million, indicating high earnings quality where cash backs reported profits. See 20/20 Biolabs, Inc. Common Stock free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of 20/20 Biolabs, Inc. Common Stock (2021–2022)
Cash flow quality index of 20/20 Biolabs, Inc. Common Stock from 2021 to 2022. Historical Cash Flow Quality Index for 20/20 Biolabs, Inc. Common Stock across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore AIDX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
20/20 Biolabs, Inc. Common Stock Cash Flow Quality Index by Year (2021–2022)
20/20 Biolabs, Inc. Common Stock cash flow quality index by year from 2021 to 2022. Year-by-year earnings quality comparison for 20/20 Biolabs, Inc. Common Stock. For the full cash flow conversion analysis, see AIDX cash flow conversion.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 2.65x | $5.80 Million | $2.19 Million | ▲ +611.9% |
| 2021 | -0.52x | $-1.07 Million | $2.07 Million | — |